Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

155
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
155
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Cancer Survival Analysis01:21

Cancer Survival Analysis

458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

156
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
156
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

47
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
47
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

234
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
234

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Value of the Novel Age-Agnostic DIPSS-R Versus the DIPSS for Prognostication in Myelofibrosis: A Multicenter Evaluation and Reclassification Study.

Cancers·2026
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

Early Peripheral Blood <i>WT1</i> Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

International journal of molecular sciences·2026
Same author

Impact of Atrial Fibrillation on Thrombotic Complications in Myeloproliferative Neoplasms Real-World Analysis.

Thrombosis and haemostasis·2026
Same author

Differentiating polycythemia vera from sodium-glucose cotransporter 2 inhibitor-associated polycythemia.

Acta diabetologica·2026
Same author

Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience.

Frontiers in oncology·2026

Related Experiment Video

Updated: Sep 19, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.6K

Thrombo-vera: a new thrombosis risk model for polycythemia vera using modern variable selection methods.

Isidora Arsenovic1, Natasa Milic2,3, Nikola Grubor2

  • 1Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia.

Expert Review of Hematology
|June 16, 2025
PubMed
Summary

A new clinical score, ThromboVera CS, effectively predicts thrombosis risk in polycythemia vera (PV) patients. This tool aids early intervention for high-risk individuals, potentially improving outcomes.

Keywords:
Artificial intelligencemyeloproliferative neoplasmspolycythemia verapredictionthrombosis

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.6K

Related Experiment Videos

Last Updated: Sep 19, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.6K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.6K

Area of Science:

  • Hematology
  • Oncology
  • Statistics

Background:

  • Thrombosis is a significant complication in polycythemia vera (PV), leading to increased morbidity and mortality.
  • Predictive models are needed to identify PV patients at high risk for thrombotic events.

Purpose of the Study:

  • To develop and validate a predictive model for thrombosis risk in polycythemia vera (PV) patients.
  • To create a clinical score for stratifying PV patients into different risk categories for thrombosis.

Main Methods:

  • Retrospective study of 817 consecutive PV patients with a median follow-up of 59 months.
  • Utilized Bayesian logistic regression with R2D2 priors to predict thrombosis.
  • Developed the ThromboVera CS score based on key predictors identified through multivariate analysis.

Main Results:

  • Thrombotic events occurred in 13.2% of PV patients.
  • Key predictors of thrombosis included Charlson Comorbidity Index (CCI), platelet-to-lymphocyte ratio (PLR), splenomegaly, and microvascular symptoms.
  • The ThromboVera CS score stratified patients into low (6.94% thrombosis), moderate (15.76%), and high-risk (48.78%) groups.

Conclusions:

  • The ThromboVera CS score is a reliable and user-friendly tool for predicting thrombosis in PV.
  • Early identification of high-risk PV patients using ThromboVera CS can facilitate timely interventions.
  • This score has the potential to significantly improve patient outcomes by enabling targeted management strategies.